混合细菌疫苗辅助治疗原发性肝癌——实验与临床研究  

LIVER CANCER TREATED SUPPLEMENTARILY WITH MIXED BACTERIAL VACCINE——EXPERIMENTAL AND CLINICAL STUDIES

作　　者：周海燕[1] 汤钊猷[1] 林芷英[1] 刘康达[1] 包炎明[1] 蔡立勉[1] 张予[1] 

机构地区：[1]上海医科大学肝癌研究所

出　　处：《肿瘤》1989年第6期249-250,共2页Tumor

摘　　要：混合细菌疫苗(MBV)是由化脓性链球菌和沙雷氏菌灭活制备的一种生物调变剂,早年称Coley毒素,用于肿瘤临床已一世纪。文献表明MBV对多种肿瘤有部分消退作用,可促进免疫防御系统,增加巨噬细胞与自然杀伤细胞活性,诱导干扰素生成及产生高热杀肿瘤效应等。本文总结了1985～1987年间使用MBV治疗原发性肝癌的实验与临床结果。Based on a promising result obtained from treating human liver cancer transplanton nude mouse with mixed bacterial vaccine (MBV), MBV was used on 73 cases ofprimary liver cancer. MBV combined with radiotherapy and chemotherapy elicited amore satisfactory. response than each of the three treatments given alone. The macro-phage activity was aroused. The survival rate from post-operative MBV treatmentwas the highest. MBV treatment is an immunotherapy, its auxiliary curative effecton liver cancer is feasible.

关 键 词：混合细菌疫苗 肝肿瘤 

分 类 号：R735.705[医药卫生—肿瘤]